News & stories – CEPI

Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

Could chicken eggs help end the COVID-19 pandemic?

CEPI is supporting PATH's work as part of an international consortium developing a new egg-based vaccine to tackle COVID-19, inspired by influenza vaccines in longtime use.

CEPI opens Call to evaluate fractional COVID-19 booster and third shots as part of efforts to stretch global vaccine supply

CEPI will make up to US $25m funding available as part of the Call, with the intention to fund several clinical trials looking at dose-sparing booster shots for different COVID-19 vaccine candidates.

University of Oxford's Prof. Dame Sarah Gilbert and CEPI's Dr. Richard Hatchett: “No one is safe, until we are all safe”

In a jointly authored letter, published in Science Translational Medicine, they call for urgent action to address the ongoing disparity in COVID-19 vaccination levels in low-income countries compared to high-income countries.

Further vaccine R&D is critical to end the devastating COVID-19 pandemic

Increased investment in ongoing vaccine R&D efforts will enable COVAX to deliver on its promises and ensure that our vaccines remain safe and effective against the emerging SARS-CoV-2 strains.

Global leaders commit further support for global equitable access to COVID-19 vaccines and COVAX

Joint statement from COVAX following the Global COVID-19 Summit hosted by the United States

Clover Biopharmaceuticals announces positive efficacy data from Phase 2/3 trial

SCB-2019 (CpG 1018/Alum) demonstrated significant efficacy against multiple variants of COVID-19, including Delta

Two expert health leaders join CEPI Board

World-leading health experts Dr. Nísia Trindade Lima and Dr. Juan Pablo Uribe have been appointed to the CEPI Board.

Joint COVAX statement on Supply Forecast for 2021 and early 2022

According to its latest Supply Forecast, COVAX expects to have access to 1.425 billion doses of vaccine in 2021.

Comparator vaccines are needed if vital COVID-19 R&D is to progress

Governments, developers, and particularly vaccine manufacturers, must urgently agree upon a solution to unlock supplies, writes CEPI's Director of Vaccine R&D, Melanie Saville.

Zalgen Awarded CEPI Contract to Provide Test Kits for Largest Ever Lassa Fever Study in West Africa

The study, Enable, seeks to better understand the rate, location, and spread of Lassa virus across the region, while also informing the location and implementation of future late-stage trials of Lassa vaccines.

CEPI partners, IVI and BBIL, launch global Chikungunya vaccine Phase II/III trial in Costa Rica

IVI is leading the Global Chikungunya vaccine Clinical Development Program consortium in partnership with Bharat Biotech, and with support from CEPI and Ind-CEPI.

Twitter

Follow

Tweets by CEPIvaccines

Media enquiries

Get involved in our cause

Become a partner